Expression And Significance Of Occludin In Human Cervical Cancer Tissues And Hela Cells Pre-and Pos-Treated With Different Drugs

Part Ⅰ Expression and clinical significance of occludin in humancervical cancer tissuesObjective: To investigate the relationship between expression of tight junction proteinoccludin and genesis, development, metastasis and prognosis in human cervical cancer.Methods: In situ hybridization (ISH) was used to detect occludin mRNA expression.Immunohistochemistry (IHC) and Western blotting were used to detect occludin proteinexpression, and the results were analyzed by combining with clinical data. Results:Remarkable relationship was found among occludin mRNA expression, cervical cancergross type and histologic differentiation (P<0.05). Remarkable relationship was foundbetween occludin protein expression and cervical cancer histologic differentiation(P<0.05). The expression of occludin protein in paracancerous cervical tissues washigher than that of tumor tissues (P<0.05). There were significant differences inoccludin protein expression between cervical cancer tissues (0.71±0.07) andparacancerous cervical tissues (0.78±0.06)(P<0.01) as well as between cervical cancertissues and relatively normal cervical tissues (0.94±0.04)(P<0.01). The expression ofoccludin mRNA and occludin protein in survival patients who were followed-up for5years and3years was higher than that of those patients who died (P<0.05). Conclusion:The expression of tight junction protein occludin is low in human cervical cancer, ispositive correlation with the histologic differentiation of cervical cancer and survivaltime of patients, it might be a new indicator for cervical cancer diagnosis and prognosisjudgement. Part Ⅱ Expression and significance of occludin in Hela cells Pre-andPos-treated with cisplatin, matrine and tetramethylpyrazineObjective: To investigate the effect of cisplatin, matrine, tetramethylpyrazine, cisplatinand matrine, cisplatin and tetramethylpyrazine on the proliferation in human cervicalcancer Hela cells, to seek their relationship with expression of tight junction proteinoccludin and their significance. Methods: MTT assay was used to determine the effectof cisplatin, matrine, tetramethylpyrazine, cisplatin and matrine, cisplatin andtetramethylpyrazine on cell proliferation. In situ hybridization was used to detectoccludin mRNA expression. Immunohistochemistry was used to detect occludin proteinexpression. Results: The proliferation of Hela cells was significantly inhibited incisplatin group, matrine group, tetramethylpyrazine group, cisplatin and matrine group,cisplatin and tetramethylpyrazine group compared with the control group (P<0.01). Theinhibition ratio of cisplatin and matrine group, cisplatin and tetramethylpyrazine groupto the growth of Hela was higher compared with the cisplatin group (P<0.05). Theexpression of occludin mRNA and occludin protein in cells was significantly increasedin cisplatin group, matrine group, tetramethylpyrazine group, cisplatin and matrinegroup, cisplatin and tetramethylpyrazine group compared with the control group(P<0.05). Conclusion: Cisplatin, matrine, tetramethylpyrazine, cisplatin and matrine,cisplatin and tetramethylpyrazine could inhibit proliferation of human cervical cancerHela cells and upregulating the expression of occludin in cells. When treatment withcombination of cisplatin and matrine, cisplatin and tetramethylpyrazine, the inhibitoryeffect on proliferation was markedly enhanced compared with single of cisplatin. Therole of anticancer drugs may be associated with upregulating the expression of occludinin Hela cells.